management

01

The company is strategically oriented toward increasing exports and developing new products that meet the needs of the demanding foreign market, so in the countries of central and eastern Europe, where it has its branches and companies, it's developing and growing.


Foreign market

18

European export markets

350

Belupo employees abroad

markets

Today, apart from Croatia, Belupo operates on 18 European pharmaceutical markets. The drive to conquer new markets remains a priority and the only way to continue to grow. In the next period, our strategic goals are the deeper penetration of CEE and SEE markets, especially the CIS countries, more focus on several new groups and further diversification of the current portfolio. In the global structure of the product portfolio, we are planning a turnaround in terms of developing new products and a stronger involvement of OTC products in the overall sales of the regional as well as the global market.

strategy

our strategic goals are further penetrating the CEE and SEE markets, especially the CIS countries


vizija

02

The be the most reliable partner on the healthcare journey.​


Our goals

01

Excellence

securing competitiveness

02

Passion

Enthusiasm and dedication to work

03

Trust

corporate social responsibility

04

Pleasure

communication

05

Creativity and innovation

innovative solutions


With quality as an imperative we create a desirable workplace in a modern organization with open communication that promotes creativity in everything we do.

strategy

The development of new products and the increase in sales, both domestically and on 18 European export markets, are the strategic orientation of all 1300 Belupo employees. The growth strategy of the company is achieved through a combination of organic and inorganic growth - with a strong focus on internationalization of business and strengthening of market share in the Republic of Croatia.

partners

Thanks to its position on the market, business approach and behavior, technological capabilities and production potential, Belupo has gained trust of respectable pharmaceutical manufacturers with whom Belupo achieves a diverse and successful co-operation. Among them, Abbott, Pharmathen, Medis, Lupin, Torrent stand out.

employees

Belupo's strength are its employees. Thanks to their enthusiasm, the desire to prove, dedication to work, home loyalty and the balance of experience and youth, Belupo is growing all these years.

About 1300 employees work in Belupo.

Belupo without the skills, knowledge and capabilities of its most educated staff cannot imagine its future. Continuous exchange of experience and acquisition of new knowledge of Belupo's employees on postgraduate studies, seminars, congresses and symposiums across Croatia and Europe is a prerequisite for Belupo's new successes.


leadership

03

Hrvoje Čeović is Chairman of the Management Board and member of the Management board is Tihomir Heđever. The Chairman of the Supervisory Board is Martina Dalić, and the members of the Board are Petar Miladin, Davor Doko, Ines Ignjatović and Željko Dragec. The President of the Audit Committee is Davor Doko, and the member is Martina Dalić.

Board

Hrvoje Čeović

Chairman of the Management Board

Belupo’s new Chairman of the Management Board Hrvoje Čeović, PhD, spent almost thirty years working in different positions at the U.S. giant Procter & Gamble, including as Sales Director for South and Central Europe, OTC Operations & Pharmacies Director for EMEA, and Vice President for Central Europe from 2014 to 2020.

biography>

Tihomir Heđever

Belupo's Member of the Management Board

Tihomir Heđever, M.Econ., was appointed a new reinforcement to the two-man Management Board. Tihomir Heđever joined the company after working at multinational auditors KPMG where he was Senior Manager at the Audit Department.

biography>

Supervisory Board

Martina Dalić

President of the SUPERVISORY BOARD and member of the audit committee

Martina Dalić, Ph.D., was appointed new President of Podravka d.d. in January of 2021 and will be appointed Chairwoman of the Supervisory Board in Belupo at the next Shareholders' Meeting of the Company.

biography>

Petar Miladin

member of Supervisory Board

He was employed at the Law Faculty in Zagreb in 1997 as a junior assistant at the Department for Commercial Law and Companies Law.

biography>

Ines Ignjatović

Member of Supervisory Board

In May 2023, she was appointed a member of the Supervisory Board of Belupo.

biography>

Željko Dragec

SUPERVISORY BOARD MEMBER

In April of 2025, he was elected Chairman of Belupo’s Works Council and employees’ representative on Belupo’s Supervisory Board.

biography>

Davor Doko

member of Supervisory Board and president of the audit committee

He started his professional career in 2000 in Assets Management department at Zagrebačka banka as assistant portfolio manager, where he participated in founding the company for managing investment funds at Zagrebačka banka.

biography>

Audit Committee

Davor Doko

member of Supervisory Board and president of the audit committee

He started his professional career in 2000 in Assets Management department at Zagrebačka banka as assistant portfolio manager, where he participated in founding the company for managing investment funds at Zagrebačka banka.

biography>

Martina Dalić

President of the SUPERVISORY BOARD and member of the audit committee

Martina Dalić, Ph.D., was appointed new President of Podravka d.d. in January of 2021 and will be appointed Chairwoman of the Supervisory Board in Belupo at the next Shareholders' Meeting of the Company.

biography>

history

04

We have been manufacturing drugs since 1971. In 1980 we modernized and expanded production with a factory in Koprivnica. In 1999, a 7,000-square-foot facility is built at world standards. 2004 begins a new cream, fat, lotion and gel factory. In 2005, a microbiological laboratory was built. In the 21st century, development did not stop: a cream and gel factory and new markets were opened. 2015 begins construction, and in 2017 manufacturing in a new solid, semi-liquid and liquid drug factory.

yesterday, today, tomorrow

1970

Podravka is starting to prepare for pharmaceutical-chemical production ie creates the prerequisites for entering a new strategic business area

start a historical review

investors

05

We report on business operations and business events in a timely, transparent and continuous manner. We allow quick and easy access to information of interest to the financial community.

business results

In the Pharmaceuticals segment, revenue of HRK 978,4 million was generated in 2020, which is an increase of 2,2 percent compared to the comparable period in 2019.